Bitte verwenden Sie diesen Link, um diese Publikation zu zitieren, oder auf sie als Internetquelle zu verweisen: https://hdl.handle.net/10419/4239 
Erscheinungsjahr: 
2007
Schriftenreihe/Nr.: 
Kiel Working Paper No. 1371
Verlag: 
Kiel Institute for the World Economy (IfW), Kiel
Zusammenfassung: 
This paper develops a real options approach to the optimal sequencing of antiretroviral drug cocktails for HIV/AIDS patients in resource-poor settings. The analysis focuses on the implications of endogenous resistance mutations in the virus that reduce or eliminate the effectiveness of individual drugs within a cocktail when lack of laboratory equipment prevents these from being identified. Using a model with two drug cocktails, we show that the first-line therapy should be introduced later than in the case without resistance mutations and that the second-line therapy should be introduced earlier. We go on to discuss implications for comparative cost-effectiveness analyses.
Schlagwörter: 
Real option theory
Cost-effectiveness analysis
Combination therapy
Developing countries
HIV/AIDS
JEL: 
D81
H51
I12
Dokumentart: 
Working Paper

Datei(en):
Datei
Größe
193.16 kB





Publikationen in EconStor sind urheberrechtlich geschützt.